Medical insurance reimbursement conditions for Ripretinib

Ripretinib The original drug has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. Adult patients with advanced gastrointestinal stromal tumors (GIST) who have received three or more kinase inhibitors (including imatinib) in the past and do not meet the conditions can only purchase it at their own expense. The reimbursement ratio is different in different regions, and the price after reimbursement may be different.

The efficacy and safety of repetinib as a fourth-line therapy was studied in a placebo-controlled trial called INVICTUS. Patients were randomly assigned to receive 150 mg of repetinib or matching placebo orally once daily, along with best supportive care. In the event of disease progression, patients receiving repetinib were allowed to increase their dose to 150 mg twice daily, and patients receiving placebo could switch to repetinib. In the repotinib group, 9.4% of patients responded to treatment, compared with no patients in the placebo group. Repetinib also improved median progression-free survival and overall survival.

The price of a box of 50mg*30 tablets of Ripetinib original drug listed in China may be around RMB 30,000. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.